OpenLB
Open Library of Bioscience
Advanced Search
Antibiotics (Basel, Switzerland)
Aug 04, 2021;10 (8):

Anti-Virulence Activity of the Cell-Free Supernatant of the Antarctic Bacterium sp. TAE2020 against Clinical Isolates from Cystic Fibrosis Patients.

Rosanna Papa, Gianluca Vrenna, Caterina D'Angelo, Angela Casillo, Michela Relucenti, Orlando Donfrancesco, Maria Michela Corsaro, Ersilia Vita Fiscarelli, Vanessa Tuccio Guarna Assanti, Maria Luisa Tutino, Ermenegilda Parrilli, Marco Artini, Laura Selan
Author Information
  1. Rosanna Papa: Department of Public Health and Infectious Diseases, Sapienza University, p.le Aldo Moro 5, 00185 Rome, Italy.
  2. Gianluca Vrenna: Department of Public Health and Infectious Diseases, Sapienza University, p.le Aldo Moro 5, 00185 Rome, Italy.
  3. Caterina D'Angelo: Department of Chemical Sciences, Federico II University, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy.
  4. Angela Casillo: Department of Chemical Sciences, Federico II University, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy.
  5. Michela Relucenti: Department of Anatomy, Histology, Forensic Medicine and Orthopaedics, Sapienza University of Rome, Via Alfonso Borelli 50, 00161 Rome, Italy. ORCID
  6. Orlando Donfrancesco: Department of Anatomy, Histology, Forensic Medicine and Orthopaedics, Sapienza University of Rome, Via Alfonso Borelli 50, 00161 Rome, Italy.
  7. Maria Michela Corsaro: Department of Chemical Sciences, Federico II University, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy. ORCID
  8. Ersilia Vita Fiscarelli: Unit Cystic Fibrosis Diagnostic Microbiology and Immunology Diagnostics, Diagnostic Medicine and Laboratory Department, Bambino Gesù Children's IRCCS Hospital, 00165 Rome, Italy. ORCID
  9. Vanessa Tuccio Guarna Assanti: Unit Cystic Fibrosis Diagnostic Microbiology and Immunology Diagnostics, Diagnostic Medicine and Laboratory Department, Bambino Gesù Children's IRCCS Hospital, 00165 Rome, Italy.
  10. Maria Luisa Tutino: Department of Chemical Sciences, Federico II University, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy. ORCID
  11. Ermenegilda Parrilli: Department of Chemical Sciences, Federico II University, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy. ORCID
  12. Marco Artini: Department of Public Health and Infectious Diseases, Sapienza University, p.le Aldo Moro 5, 00185 Rome, Italy.
  13. Laura Selan: Department of Public Health and Infectious Diseases, Sapienza University, p.le Aldo Moro 5, 00185 Rome, Italy.
PMID: 34438994 DOI: 10.3390/antibiotics10080944

Abstract

is an opportunistic pathogen often involved in airway infections of cystic fibrosis (CF) patients. Its pathogenicity is related to several virulence factors, such as biofilm formation, motility and production of toxins and proteases. The expression of these virulence factors is controlled by quorum sensing (QS). Thus, QS inhibition is considered a novel strategy for the development of antipathogenic compounds acting on specific bacterial virulence programs without affecting bacterial vitality. In this context, cold-adapted marine bacteria living in polar regions represent an untapped reservoir of biodiversity endowed with an interesting chemical repertoire. In this paper, we investigated the biological activity of a supernatant derived from a novel Antarctic bacterium (SN_TAE2020) against specific virulence factors produced by strains isolated from FC patients. Our results clearly show a reduction in pyocyanin and protease production in the presence of SN_TAE2020. Finally, SN_TAE2020 was also able to strongly affect swarming and swimming motility for almost all tested strains. Furthermore, the effect of SN_TAE2020 was investigated on biofilm growth and texture, captured by SEM analysis. In consideration of the novel results obtained on clinical strains, polar bacteria might represent potential candidates for the discovery of new compounds limiting virulence in CF patients.

Keywords

Antarctic bacteria Pseudomonas aeruginosa SEM anti-virulence biofilm cystic fibrosis motility proteases pyocyanin

References

Biofouling. 2018 Nov;34(10):1110-1120 [PMID: 30698031]
mBio. 2021 May 4;12(3): [PMID: 33947765]
Appl Environ Microbiol. 2011 May;77(9):3061-7 [PMID: 21378043]
Nat Rev Drug Discov. 2010 Feb;9(2):117-28 [PMID: 20081869]
Biofouling. 2018 Apr;34(4):410-425 [PMID: 29745728]
Trends Microbiol. 2016 May;24(5):327-337 [PMID: 26946977]
Molecules. 2018 Feb 23;23(2): [PMID: 29473844]
PLoS One. 2011;6(12):e29113 [PMID: 22216178]
Antibiotics (Basel). 2018 Oct 19;7(4): [PMID: 30347637]
Future Microbiol. 2019 Nov;14:1369-1382 [PMID: 31596138]
Front Microbiol. 2017 May 03;8:769 [PMID: 28515715]
Biology (Basel). 2021 Jan 12;10(1): [PMID: 33445707]
Nat Chem Biol. 2006 Feb;2(2):71-8 [PMID: 16421586]
Curr Top Med Chem. 2017 Jan 05;: [PMID: 28056745]
Pathogens. 2014 Aug 18;3(3):680-703 [PMID: 25438018]
Sensors (Basel). 2020 Sep 13;20(18): [PMID: 32933125]
Pathog Dis. 2013 Apr;67(3):159-73 [PMID: 23620179]
Front Microbiol. 2018 Jan 09;8:2640 [PMID: 29375509]
Food Chem Toxicol. 2020 Jul;141:111431 [PMID: 32417365]
Annu Rev Microbiol. 2002;56:187-209 [PMID: 12142477]
Sci Rep. 2020 Feb 14;10(1):2653 [PMID: 32060344]
Anal Chim Acta. 2017 Mar 15;958:59-70 [PMID: 28110685]
Microorganisms. 2020 May 27;8(6): [PMID: 32471210]
Front Pharmacol. 2021 Mar 11;12:581645 [PMID: 33776759]
Front Microbiol. 2015 Dec 14;6:1333 [PMID: 26696962]
Microb Pathog. 2021 Jan;150:104693 [PMID: 33352215]
Antimicrob Agents Chemother. 2006 Nov;50(11):3674-9 [PMID: 16966394]
Pulm Pharmacol Ther. 2008 Aug;21(4):595-9 [PMID: 18234534]
J Clin Invest. 2003 Nov;112(9):1300-7 [PMID: 14597754]
Appl Environ Microbiol. 2014 Nov;80(21):6724-32 [PMID: 25172852]
Chemistry. 2011 Jun 14;17(25):7053-60 [PMID: 21557359]
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5217-20 [PMID: 26453007]
PLoS Pathog. 2014 Aug 21;10(8):e1004321 [PMID: 25144274]
Scanning. 2020 Feb 15;2020:9371516 [PMID: 32158510]
Res Microbiol. 2013 Jun;164(5):450-6 [PMID: 23411371]
Appl Microbiol Biotechnol. 2015 May;99(10):4145-73 [PMID: 25874533]
Respir Care. 2009 May;54(5):641-57 [PMID: 19393108]
Front Cell Infect Microbiol. 2017 Feb 23;7:46 [PMID: 28280714]
Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1077-86 [PMID: 12871859]
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308 [PMID: 23458769]
J Microbiol Biotechnol. 2017 Jun 28;27(6):1053-1064 [PMID: 28301918]
Int J Mol Sci. 2021 Mar 18;22(6): [PMID: 33803907]
Lancet. 2009 May 30;373(9678):1891-904 [PMID: 19403164]
Int J Mol Sci. 2020 Dec 04;21(23): [PMID: 33291608]
J Ind Microbiol Biotechnol. 2016 Mar;43(2-3):155-76 [PMID: 26739136]
Arch Med Res. 2021 May;52(4):357-361 [PMID: 33309309]
Genes Dev. 2001 Jun 15;15(12):1468-80 [PMID: 11410527]

Grants

  1. PNRA 2013 prot. 0030683.13-12-2013/Ministero dell'Istruzione, dell'Università e della Ricerca
Journal Article

Word Cloud

Similar Articles

Cited By